Discuss how unregulated FDI in the hospital sector can conflict with the constitutional goal of affordable healthcare. Suggest a regulatory framework balancing foreign investment and public welfare.

Affordable healthcare flows from Article 21 (right to health as part of life) read with Article 47's directive to raise public health standards. India permits 100% FDI in hospitals under the automatic route [3], which built world-class capacity but, as the Parliamentary Standing Committee on Health and Family Welfare's 176th Report (August 2026) warns, is now enabling "aggressive corporatisation" that inflates costs [1].

How unregulated FDI conflicts with affordability

• Ownership concentration: foreign capital lets large corporate chains acquire cost-effective mid-sized hospitals, removing the affordable tier on which lower- and middle-income patients depend [1].
• Price escalation: consolidation reduces competition and raises treatment, diagnostics and room charges; the Committee therefore sought a mechanism to standardise and cap costs of essential treatments and routine procedures across private hospitals [1].
• Financial burden: though out-of-pocket expenditure fell to 43.4% of total health expenditure in 2022-23 [4], it remains a leading cause of impoverishment — cost inflation directly erodes this gain.
• Distorted priorities: investment chases high-margin tertiary and medical-tourism segments in metros rather than underserved primary care, deepening regional inequity [2].
• Regulatory mismatch: FDI is a Union subject while public health and hospitals are largely a State subject, leaving ownership changes effectively unsupervised at the point of delivery [1].

A balancing framework

• Rationalise, not prohibit: review FDI limits on acquisition and operation of existing hospitals, while actively channelling FDI into medical devices, consumables and rare-disease medicines [1].
• Sectoral scrutiny: DPIIT–Health Ministry vetting of large hospital acquisitions, with CCI review of market concentration.
• Cross-subsidisation: bind FDI-backed advanced facilities to a structured obligation to serve domestic and low-income patients [2].
• Price transparency: enforce the Clinical Establishments Act, 2010 with standardised rate display and grievance redress.

Foreign capital and affordability are reconcilable if investment is steered toward capacity creation rather than ownership churn. A calibrated, transparent regime — investment-friendly yet accountable — would let India remain a global medical destination while advancing Universal Health Coverage and SDG-3.